Emerging Trends in the Sequencing and Combination of Therapies for Advanced Melanoma

An interactive learning experience designed to provide users with immersive learning. Answer questions and take digital notes throughout.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

  • Overview

    Before the Activity: Important Instructions

    Make sure you are logged in to your ReachMD account before accessing program. 

    Not registered? Click to register with ReachMD. Then, come back to this page to complete the CME program.

    Throughout the program, you will have the opportunity to answer polls, view related educational content, and take digital notes for later viewing. 

    Activity Overview

    Melanoma is the sixth most common cancer in the United States, and the number of melanoma cases diagnosed annually is increasing faster than for any other cancer. The medical management of melanoma has changed dramatically since its first description as a disease entity. In this educational activity, leading oncologists will discuss the mechanisms of action, clinical safety, and efficacy profiles of new, as well as emerging therapies, and the use of biomarkers to select regimens and will review evidence-based clinical trial data supporting the medical treatment of advanced melanoma.

  • Learning Objectives

    Upon successful completion of this educational activity, participants should be better able to:

    • Describe the mechanisms of action, as well as the clinical safety and efficacy profiles, of new and emerging therapies for the treatment of advanced melanoma.
    • Evaluate the use of biomarkers to guide clinical decision making for advanced melanoma.
  • Target Audience

    The intended audience for the activities is medical oncologists, dermatologists, and other health care professionals involved in the treatment of patients with melanoma.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page. 

    The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

    Faculty members reports the following relationship(s):

    Sanjiv S. Agarwala, MD
    Professor of Medicine, Temple University School of Medicine, and Chief, Oncology and Hematology, St. Luke's Cancer Center, Bethlehem, PA.

    Disclosure:
    No relevant financial relationships to disclose.

    Steven J. O’Day, MD 

    Director, Los Angeles Skin Cancer Institute, and Director, Clinical Research Beverly Hills Cancer Center, Beverly Hills, CA

    Disclosure:
    Consulting Fee: Bristol-Myers Squibb, Merck, Novartis
    Speakers Bureau: Bristol-Myers Squibb
    Contracted Research: Incyte, Merck

    Merrick I. Ross, MD
    Professor of Surgery and Chief of the Melanoma Section at the University of Texas-M.D. Anderson Cancer Center, Houston, TX.

    Disclosure:
    Consulting Fee: Amgen, GlaxoSmithKline, Merck, Provectus
    Speakers Bureau: Amgen, GlaxoSmithKline, Provectus,
    Other: Travel Expenses/Honorarium for Amgen, GlaxoSmithKline, Merck, Provectus

    Reviewers report the following relationship(s):

    Jason Luke, MD
    Consulting Fee: Amgen, Array
    Contracted Research: BBI Therapeutics, Bristol-Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, MedImmune, Merck, Novartis, Pharmacyclics

    Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
    No relevant financial relationships to disclose.

    Vindico Medical Education staff report the following relationship(s):
    No relevant financial relationships to disclose.
    Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

  • Accreditation and Credit Designation Statements

    This continuing medical education activity is provided by 

    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an educational grant from Merck & Co., Inc.

  • Terms of Use

    How To Participate in this Activity and Obtain CME Credit:
    To participate in this CME activity, you must read the objectives, answer the pretest question, view content, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

     

  • Disclaimer

    Unlabeled and Investigational Usage:
    The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

    Copyright Statement:
    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    CME Questions?
    Contact us at cme@vindicoCME.com

     

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

NEW FEATURES: